NEXON Co., Ltd. is issuing 2,749,912 stock options as part of its 30th round of director remuneration, approved during the March 25, 2026, Annual General Meeting of Shareholders.
See it on page 1The stock options are scheduled for issuance on April 10, 2026, with each unit convertible into one share of common stock.
See it on page 1The grant is restricted to current directors, specifically covering two individuals who are not members of the Audit and Supervisory Committee, one of whom is an external director.
See it on page 2Recipients are granted a ten-year exercise period starting from the April 10, 2026, grant date, provided they generally remain directors of the company.
See it on page 2The options are issued without requiring cash payment and include standard anti-dilution adjustment mechanisms for corporate actions like stock splits or mergers.
See it on page 2NEXON retains the right to acquire the options without payment in specific restructuring scenarios, such as corporate demergers or share exchanges, and requires Board approval for any transfer of the options.
See it on page 2NEXON Co., Ltd. has authorized the issuance of the 30th round of stock acquisition rights to its Board of Directors, following approval at the 24th Annual General Meeting of Shareholders held on March 25, 2026. This initiative serves as a component of director remuneration, aligning executive incentives with the company’s long-term performance. The grant involves 2,749,912 units of stock options, each convertible into one share of common stock, to be issued on April 10, 2026.
The program is restricted to current directors, including two individuals who are not members of the Audit and Supervisory Committee, one of whom is an external director. These options are granted without requiring cash payment and carry an exercise period of ten years from the grant date. To maintain eligibility, holders must generally remain directors of the company at the time of exercise, though specific provisions allow for exceptions in cases of retirement, resignation, or death.
The terms include standard adjustment mechanisms for corporate actions such as stock splits, consolidations, or mergers. Furthermore, the company retains the right to acquire the options without payment under specific restructuring scenarios, including mergers, corporate demergers, or share exchanges. Any transfer of these options requires prior approval from the Board of Directors. Upon exercise, the increase in paid-in capital and capital reserves will be determined based on statutory accounting standards, with the issuance designed to comply with the Companies Act of Japan.